X

Trial Profile

Phase I/IIa study of EncorStat (OXB-202) for the prevention of corneal graft rejection

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OXB 202 (Primary)
Indications Keratoplasty rejection
Focus Adverse reactions

Most Recent Events

16 Mar 2017 According to an Oxford BioMedica media release, the company has been working on appropriate regulatory approval for the initiation of a Phase I/II clinical study in the United Kingdom.
21 Feb 2014 New trial record
17 Feb 2014 As confirmed on 19 November 2013, Oxford BioMedica was awarded a EUR1.8 million grant by the UK's Technology Strategy Board, which will facilitate the funding of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com